MP52-09 MULTICENTRIC PROSPECTIVE LOCAL TREATMENT OF METASTATIC PROSTATE CANCER (LOMP) TRIAL: INTERIM ANALYSIS OF CLINICAL OUTCOMES AND PROGNOSTIC FACTORS

RESULTS: Median PSA at PET/CT scan was 2.9 ng/ml (IQR 1.2-6.1).Open and laparoscopic sLND were performed in 40/52 (77%) and 12/52 (23%), respectively.Median number of removed lymph nodes was 6 (IQR 4-13).Histological report was positive for PCa in 39/ 52 sLND (75%).Gr A consisted of 7 pts and 2 had sTF.Gr B and C consisted of 12 and 22 pts and all had sTF.Lost to follow up 5 pts.Median PSA before sLND in gr A, B, C were 1.2 (IQR 0.3-2.6),3.4 (IQR 1-18) and 3.7 ng/ml (IQR 2.4-6.2),respectively.Median PSA nadir in gr B and C was 1.4 (IQR 0.3-2.6)and 2.6 ng/ml (IQR 0.9-4.4),respectively.Median time to sTF was 3.5 (IQR 1.7-13.2) and 4 months (IQR 2.0-10) for gr B and C.Only 5 of 46 pts were long-term free of recurrence.Median blood loss was <50 ml (IQR 0-50, range 0-600).Median length of hospital stay was 5 days (IQR 4-6).Postoperative complications were recorded in 11 pts (Clavien-Dindo (CD) I-II: 4 pts, CDIII: 7 pts).Readmission rates at 30d and 90d were 5/52 (9.6%) and 1/52 (2%), respectively.Mortality was 0/52.CONCLUSIONS: Spot-specific PET/CT sLND harbors a measurable (CDIII) morbidity in 1 out of 7 pts while facing an unclear oncological benefit.Only pts with positive histological report and a PSA nadir <0.01 ng/ml after sLND seem to have a long-term benefit.Pts with a PSA nadir >0.01ng/ml have a delay of systemic treatment of up to 4 months.Only 5 of 46 pts were long-term free of recurrence.